



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

May 28, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Subject: Newspaper Advertisement- Regulation 47 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 30 read with Schedule III and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper advertisement published in Financial Express and Loksatta on Thursday, May 28, 2026, containing extract of Audited Financial Results for the quarter and year ended March 31, 2026.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe

Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

MEDICAMEN BIOTECH LIMITED

Reg. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi, 110019 (India)

CIN: L74899DL1993PLC056594 Contact No.: 011-47589500

Website: www.medicamen.com Email: info@medicamen.com



Statement of Audited Financial Results (Standalone and Consolidated) for the quarter and year ended on March 31, 2026

Based on the recommendation of Audit Committee, the Board of Directors of the Company, at their meeting held on May 27, 2026, approved the audited financial results (Standalone & Consolidated) of the Company for the quarter and year ended on March 31, 2026.

The financial results along with Independent Audit Report have been posted on the website of the Company at www.medicamen.com and can be accessed by scanning the QR code given below:



For and on behalf of Board of Directors

Medicamen Biotech Limited

Sd/-

Rahul Bishnoi

Director

DIN: 00317960

Place: New Delhi

Date: 27.05.2026



DHANSAFAL FINSERVE LIMITED

(Formerly known as "Luharuka Media & Infra Limited")

CIN: L65100MH1981PLC044094

Registered Office: G-1402, Lotus Corporate Park, Goregaon East, Mumbai, Maharashtra 400063;

Phone No.: 022-6894-8500/08/09, Email: info@dhanafal.com ; Website: www.dhanafal.com

STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND FINANCIAL YEAR ENDED MARCH 31, 2026

The Board of Directors of the Company, at its Meeting held on Wednesday, May 27, 2026 have, inter-alia approved the Audited Financial Results of the Company, for the quarter and financial year ended March 31, 2026.

The results, along with the Auditors' Report thereon, have been posted on the Company's website at www.dhanafal.com/financial-result and on the website of the stock exchange where the Company's shares are listed i.e., at www.bseindia.com. Also, it can be accessed by scanning the QR code.



For and on behalf of the Board of Directors of DhanSafal Finserve Limited

Sd/-

Ankur Agrawal

Chairperson and Managing Director

DIN: 06408167

Place: Mumbai

Date: May 27, 2026

Note: The above intimation is in accordance with Regulation 33 read with Regulation 47(1) of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 and pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026.

This is only an advertisement for information purpose and not an offer document announcement. Not for publication, distribution, or release, directly or indirectly into the United States or otherwise Outside India. All Capitalized terms used and not defined herein shall have the meaning assigned to them in the Letter of Offer dated April 11, 2026 (the "Letter of Offer" or "LOF") filed with the Stock Exchange, namely BSE Limited ("BSE") and the Securities and Exchange Board of India ("SEBI").

Panafic Industrials Limited

Corporate Identity Number: L45202DL1985PLC019746

Registered Office: 23, 2nd Floor, North West Avenue, Club Road, West Punjabi Bagh, New Delhi - 110026, India

Telephone: 011-25223461, 25221200; Email: panafic.industrials@gmail.com;

Website: www.panaficindustrialsltd.in

Contact Person: Mr. Dharmender Kumar, Company Secretary and Compliance Officer;



Panafic Industrials Limited (Company or Issuer) was incorporated on January 01, 1985, as a public limited company under the Companies Act, 1956 with the Registrar of Companies, Delhi & Haryana and consequently a certificate of commencement of business dated January 16, 1985, was issued to our Company. Pursuant to a Board Resolution passed by the Board of Directors of our Company on July 17, 2014, the Registered Office of our Company was shifted from 4566-13, Jai Mata Market, Tinagar, New Delhi - 110035, India to 23, 2nd Floor, North West Avenue, Club Road, West Punjabi Bagh, New Delhi - 110026, India. The Corporate Identification Number of Our Company is L45202DL1985PLC019746. For further details please refer to the section titled "General Information" beginning on page 39 of this Letter of offer.

PROMOTERS: MS. SARITA GUPTA, MS. SAROJ GUPTA, MR. ANIL GUPTA AND MR. RAJEEV KUMAR GUPTA

ISSUE OF 41,06,25,000 FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹ 1/- EACH OF OUR COMPANY (THE RIGHTS EQUITY SHARES) FOR CASH AT A PRICE OF ₹ 1 PER RIGHTS EQUITY SHARE AGGREGATING TO ₹ 4,10,62,50,000 ON A RIGHTS BASIS TO THE ELIGIBLE EQUITY SHAREHOLDERS OF OUR COMPANY IN THE RATIO OF 5 RIGHTS EQUITY SHARES FOR EVERY 1 EQUITY SHARES HELD BY THE ELIGIBLE EQUITY SHAREHOLDERS ON THE RECORD DATE, THAT IS ON FRIDAY, APRIL 17, 2026, (THE ISSUE). FOR FURTHER DETAILS, SEE TERMS OF THE ISSUE BEGINNING ON PAGE 134 OF THE LETTER OF OFFER.

*Assuming full subscription

BASIS OF ALLOTMENT

The Board of Directors of Panafic Industrials Limited wishes to thank all its shareholders and investors for their response to the issue which opened for subscription on Friday, April 24, 2026 and closed on Friday, May 22, 2026, and the last date for market renunciation of Rights Entitlements was Monday, May 18, 2026. Out of the total 976 Applications for 41,58,93,889 Equity Shares, 369 Applications for 4,69,121 Equity Shares were rejected due to technical reasons as disclosed in the LOF. The total number of fully valid applications received were 607 Applications for 41,54,24,768 Equity Shares. In accordance with the LOF and on the basis of allotment finalized on May 25, 2026, in consultation with the Registrar to the Issue and BSE Limited being the Designated Stock Exchange for the Issue, the Company has on May 26, 2026 allotted 41,06,25,000 Equity Shares to the successful Applicants. All valid applications have been considered for Allotment.

1. Information Regarding total Applications received (i.e., Applications through ASBA process)

Category	Applications Received		Equity Shares Applied against Rights Entitlement	Additional Equity Shares applied for	Equity Shares Applied For	%
	Number	%				
Eligible Equity Shareholders	547	90.12%	1,44,83,406	15,67,18,088	17,12,01,494	41.21%
Renounees	60	9.88%	23,97,049	24,18,26,225	24,42,23,274	58.79%
Total	607	100.00%	1,68,80,455	39,85,44,313	41,54,24,768	100.00%

2. Basis of allotment

Category	Number of valid Applications Received and considered for allotment	Number of Equity Shares accepted and allotted against Rights Entitlement(A)	Number of Equity Shares accepted and allotted against additional Equity Shares applied for (B)	Total Equity Shares accepted and allotted (A+B)
Eligible Equity Shareholders	552	1,44,83,406	15,67,18,088	17,12,01,494
Renounees	60	23,97,049	23,70,26,457	23,94,23,506
Total	612	1,68,80,455	39,37,44,545	41,06,25,000

Intimations for Allotment/refund/rejection cases: The dispatch of allotment advice cum refund intimation and reason for rejection, as applicable, to the investors has been completed on May 25, 2026. The instructions to SCSBs for unlocking funds in case of ASBA Applications were given on May 25, 2026. The Listing application was executed with BSE on May 25, 2026. The credit of Equity Shares in dematerialized form to respective demat accounts of allottees is expected to be completed on or about Tuesday, May 27, 2026. For further details please see "Terms of the Issue- Allotment Advices/Refund Orders on page number 158 of the LOF. Pursuant to the listing and trading approvals to be granted by BSE, the Rights Equity Shares Allotted in the issue is expected to commence trading on BSE on or about Wednesday, June 3, 2026. In Accordance with the SEBI Master Circular bearing reference number SEBI/HO/CFD/POD-1/P/CIR/2024/0154, dated November 11, 2024, the request for extinguishment of rights entitlement has been sent to NSDL and CDSL on Tuesday, May 27, 2026.

INVESTORS MAY PLEASE NOTE THAT THE EQUITY SHARES CAN BE TRADED ON THE STOCK EXCHANGES ONLY IN DEMATERIALIZED FORM

DISCLAIMER CLAUSE OF SEBI: The Draft Letter of Offer has not been filed with SEBI in terms of SEBI ICDR Regulations, however the final letter of offer was filed with SEBI for dissemination purpose. The investors are advised to refer to the full text of the "Disclaimer clause of SEBI" beginning on page 127 of the "LOF".

DISCLAIMER CLAUSE OF BSE: (Designated Stock Exchange): It is to be distinctly understood that the aforesaid permission given by BSE should not in any way be deemed or construed that the letter of offer has been cleared or approved by BSE; nor does it in any manner warrant, certify or endorse the correctness or completeness of any of the contents of the letter of offer; nor does it warrant that this Issuer's securities will be listed or will continue to be listed on the Exchange; nor does it take any responsibility for the financial or other soundness of this Issuer, its promoters, its management or any scheme or project of this Issuer. The investors are advised to refer to the Letter of Offer for the full text of the "Disclaimer Clause of BSE" beginning on page 128 of the LOF.

ISSUER COMPANY	REGISTRAR TO THE ISSUE
<p>PANAFIC INDUSTRIALS LIMITED Corporate Identity Number: L45202DL1985PLC019746 Registered Office: 23, 2nd Floor, North West Avenue, Club Road, West Punjabi Bagh, New Delhi - 110026, India Telephone: 011-25223461, 25221200 Contact Person: Mr. Dharmender Kumar, Company Secretary and Compliance Officer Email: panafic.industrials@gmail.com, Website: www.panaficindustrialsltd.in</p>	<p>SKYLINE FINANCIAL SERVICES PRIVATE LIMITED CIN: U74899DL1995PTC071324 Registered Office: D-153A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi- 110020 Tel: 011-40450193-197; Fax: 011-26812683 Email: ipo@skylinerta.com Investor Grievance Email: grievances@skylinerta.com Website: www.skylinerta.com Contact Person: Mr. Anuj Rana SEBI Registration No.: INR000003241</p>

Investors may contact the Registrar or the Company Secretary and Compliance Officer for any pre issue or post issue related matter. All grievances relating to the ASBA process may be addressed to the Registrar, with a copy to the SCSBs in case of ASBA process, giving full details such as name, address of the Applicant contact number(s), e-mail address of the sole first holder, folio number or demat account number, number of Rights Equity Shares applied for, amount blocked (in case of ASBA process), ASBA Account number, and the Designated Branch of the SCSBs where the Application Form or the plain paper applications as the case may be, was submitted by the Investors along with a photocopy of the acknowledgement slip (in case of ASBA process).

THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARES OR THE BUSINESS PROSPECTS OF THE COMPANY.

For PANAFIC INDUSTRIALS LIMITED

On behalf of the Board of Directors

Sd/-

Mr. Dharmender Kumar

Company Secretary and Compliance Officer

Date: May 27, 2026

Place: New Delhi

The LOF is available on the website of the SEBI at www.sebi.gov.in; the stock exchange i.e BSE Limited at www.bseindia.com ; the website of the Company, www.panaficindustrialsltd.in Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled "Risk Factors" beginning on page 23 of the "LOF". The Rights Entitlements and the Rights Equity Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "US Securities Act") or under any securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, allotted, taken up, exercised, renounced, pledged, transferred or delivered, directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons (as defined in Regulation S except for these purposes, U.S. Persons include persons who would otherwise have been excluded from such term solely by virtue of Rule 902(K)(1)(VIII)(B) or Rule 902(K)(2)(I)), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States. Accordingly, the Rights Entitlements and Rights Equity Shares were offered and sold (i) in offshore transactions outside the United States to non-U.S. Persons in compliance with Regulations to existing shareholders located in jurisdictions where such offer and sale of the Rights Equity Shares is permitted under laws of such jurisdictions, and (ii) in the United States to U.S. Persons who are U.S. QIBs and are also Qualified Purchasers pursuant to applicable exemptions under the US Securities Act and the Investment Company Act.



SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.

Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(₹ In million)

Sr. No.	Particulars	Quarter ended 31-03-2026	Quarter ended 31-12-2025	Quarter ended 31-03-2025	Year ended 31-03-2026	Year ended 31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
1	Total revenue from operations	2,765.28	2,064.40	1,841.09	8,278.75	6,964.85
2	Net Profit/(Loss) for the period (before tax, Exceptional items)	921.29	673.78	640.62	2,752.37	2,484.81
3	Net Profit/(Loss) for the period before Tax (after Exceptional items)	921.29	669.20	640.62	2,747.79	2,484.81
4	Net Profit/(Loss) for the period after Tax (after Exceptional items)	742.29	496.75	503.82	2,091.20	1,879.58
5	Total Comprehensive income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax)	742.70	497.15	504.69	2,090.21	1,878.33
6	Equity Share capital	160.97	160.97	160.97	160.97	160.97
7	Other Equity				11,816.36	9,806.63
8	Earning per share (of ₹ 2/- each) (not annualised for the Quarters)					
	1. Basic	9.22	6.17	6.29	25.98	23.35
	2. Diluted	9.22	6.17	6.29	25.98	23.35

Notes:

- The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 27, 2026.
- The figures for quarters ended March 31, 2026 and March 31, 2025 are balancing figures between the audited figures in respect of the full financial year and published year to date unaudited figures upto the third quarter of the respective financial year, which were subjected to Limited Review by the Statutory Auditors.
- The above is an extract of the detailed format of Quarterly and Year Ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of the statement of financial results are available on the stock exchange websites: www.bseindia.com, www.nseindia.com and also on Company's website. The same can also be accessed by scanning the QR code provided below.



For Supriya Lifescience Limited

Sd/-

Dr. Satish Waman Wagh

Chairman and Executive Director

DIN: 01456982

Place: Mumbai

Date: May 27, 2026

Sustainability. Growth. Profitability.



Adfactors 11276

BAJAJ STEEL INDUSTRIES LIMITED

(CIN : L27100MH1961PLC011936)

Regd. Off. : Plot No. C-108, MIDC Industrial Area, Hingna, Nagpur - 440016 (MH) India.

Tel.: +91-07104-238101, Fax : 07104-237067;

Website : www.bajajngp.com; E-mail : cs_legal@bajajngp.com

EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026

(Rupees in Lakhs, except Earning Per Share)

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31/03/2026	31/03/2025	31/12/2025	31/03/2026	31/03/2025
	Audited	Unaudited	Audited	Audited	Audited
Total Income from Operations	12,234.45	15,999.60	12,909.13	53,653.67	59,720.70
Net Profit/(Loss) for the period before Exceptional Items	380.82	2,325.34	798.06	5,000.30	8,541.08
Exceptional Items - Profit/(Loss)	-	-	-	-	2,652.33
Net Profit/(Loss) for the period before tax	380.82	2,325.34	798.06	5,000.30	11,193.41
Net Profit/(Loss) for the period after tax	231.85	1,805.66	591.21	3,690.50	8,433.42
Total Comprehensive Income for the period (after tax)	291.05	1,747.48	591.21	3,749.70	8,375.24
Paid up Equity Share Capital (Face Value of Rs. 5/- Each)	1,040.00	1,040.00	1,040.00	1,040.00	1,040.00
Reserve excluding Revaluation Reserve as per balance Sheet of Previous Accounting year	-	-	-	41,357.04	37,701.55
Earning Per Share in Rupees face value of Rs 5/- Each (not annualised)	1.40	8.40	2.84	18.03	40.27

NOTES:

- Key Numbers of Audited Standalone Financial Results for the Quarter and Year ended March 31, 2026 are as under:

PARTICULARS	QUARTER ENDED			YEAR ENDED	
	31/03/2026	31/03/2025	31/12/2025	31/03/2026	31/03/2025
	Audited	Unaudited	Audited	Audited	Audited
Total Income from Operations	11,854.66	15,713.91	12,159.61	48,604.14	54,501.33
Exceptional Items - Profit/(Loss)	-	-	-	-	2,652.33
Net Profit/(Loss) for the period before Tax	274.10	2,543.63	894.44	3,816.25	10,077.48
Net Profit/(Loss) for the period after Tax	106.94	1,977.08	671.01	2,757.59	7,614.81
Total Comprehensive Income for the period (after tax)	166.15	1,918.92	671.01	2,816.80	7,556.65

- The Board of Directors, in its meeting held on May 27, 2026, has recommended a Dividend of Rs. 1/- per equity share for the financial year ended March 31, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company.
- The figures of the Last Quarter i.e. ended on March 31, 2026 are the balancing figures between the audited figures in result of full Financial Year 2025-26 and published figures for nine months ended on December 31, 2025.
- The above is an extract of the detailed format of the Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Results are available on the Stock Exchange website (www.bseindia.com) and on the Company website (www.bajajngp.com).



By Order of the Board
For Bajaj Steel Industries Limited
Sd/-
Rohit Bajaj
Chairman & Managing Director
DIN : 00511745

PLACE : Nagpur

DATE : 27.05.2026



THE BUSINESS DAILY FOR DAILY BUSINESS



FOR DAILY BUSINESS

FINANCIAL EXPRESS

Read to Lead

निरोगी पचनक्रिया आरोग्याची गुरुकिल्ली



नवी दिल्ली : सध्याचे धावपळीचे युग, त्याला अनुसरून बदलती जीवनशैली, असंतुलित आहार, 'जंक फूड'चे वाढते प्रमाण आणि तणाव आदी सर्वांचा मानवी पचनक्रियेवर परिणाम होतो. गॅस, ऑसिडिटी, बद्धकोष्ठता आणि अपचन यांसारख्या समस्या आता सामान्य झाल्या आहेत. काही जण या समस्यांकडे फारसे लक्ष देत नाहीत; परंतु याकडे वारंवार किंवा दीर्घकाळ दुर्लक्ष करणे गंभीर आजारांना आमंत्रण देणारे ठरते. शरीराची ऊर्जा, प्रतिकारशक्ती आणि सर्वांगीण आरोग्यासाठी निरोगी पचनसंस्था अत्यंत महत्त्वाची असल्याचे आरोग्य

बँक ऑफ महाराष्ट्र
Bank of Maharashtra
कार कर्ज
@ 7.45%
मिस्ट कॉल टा
8010 614 614

तज्ज्ञांनी सांगितले. २९ मे हा दिवस 'जागतिक पचन आरोग्य दिन' म्हणून साजरा केला जातो. नागरिकांना पचनसंस्थेच्या समस्या आणि त्या कशा टाळण्याच्या याबद्दल जागरूकता निर्माण करणे हा जागतिक पचन आरोग्य दिन साजरा करण्याचा उद्देश आहे.

पचनक्रियेबद्दल दक्षता घेतल्यास मोठ्या गंभीर आजारांना दूर ठेवणे शक्य होते. यासाठी संतुलित आणि पोषक, फायबरयुक्त आहार यामध्ये ताजी फळे, हिरव्या पालेभाज्या, डाळी, धान्य आदींचा समावेश असून, हा आहार आतड्यांचे आरोग्य सुस्थितीत ठेवतो. नियमित आणि योग्य प्रमाणात आहार घेतल्यास पोट नेहमी हलके राहते आणि त्यामुळे पचनक्रिया सहजतेने कार्य करते. तेलकट, तुपट किंवा जड पदार्थ टाळवेत, यामुळे पचनक्रिया बाधित होते, असा सल्ला आरोग्य तज्ज्ञांनी दिला. मानसिक तणावाचा थेट परिणाम पचनक्रियेवर होतो. त्यामुळे योग्या, ध्यान आणि पुरेशी झोप घेतल्याने तणाव कमी करता येतो, अशी माहिती आरोग्य तज्ज्ञांनी दिली.

शिवसेनाप्रमुखांचा पालिकेस विसर

ऐतिहासिक वास्तूंच्या देखभाल कंत्राटात पुतळ्याचा समावेश नाही

लोकसत्ता खास प्रतिनिधी

मुंबई : मुंबईचा पुरातन वारसा म्हणून ओळख असलेल्या वास्तूंच्या देखभालीसाठी मुंबई महापालिका आता खास कंत्राट देऊन संस्था नेमणार आहे. मात्र या वास्तू आणि पुतळ्यांच्या यादीत रिगल सिनेमाच्या चौकातील शिवसेनाप्रमुख बाळासाहेब ठाकरे यांच्या पुतळ्याचा समावेश नसल्याचा मुद्दा शिवसेना (ठाकरे) पक्षाने उपस्थित केला. त्यामुळे भाजप आणि शिवसेना (शिंदे) पक्षाच्या सदस्यांना या मुद्द्याला पाठिंबा द्यावाच लागला.

शिवसेनाप्रमुखांच्या पुतळ्याची देखभाल विभागतरवार केली जात असल्यामुळे त्याचा समावेश या यादीत केलेला नाही. तर हुतात्मा स्मारकाचा समावेश यादीत आहे. **विपीन शर्मा**, अतिरिक्त आयुक्त

शिवसेनाप्रमुखांचा विसर पडल्याची चर्चा सुरू होती. फोटो परिसरातील कारंजी, प्याऊ आणि पुतळ्यांच्या संवर्धनासाठी ३ वर्षांचा करार करण्यात येणार आहे. हा प्रस्ताव पुरातन वास्तूसाठी होता आणि शिवसेनाप्रमुखांचा पुतळा हा पुरातन वास्तू मध्ये येत नाही. पण, शिवसेनाप्रमुखांच्या पुतळ्याची देखभाल ही विभागांमार्फत करण्यात येणार आहे. तर हुतात्मा स्मारकाच्या देखभालीसाठी स्वतंत्र तरतूद करण्यात आली आहे, असे स्थायी समिती अध्यक्ष प्रभाकर शिंदे यांनी सांगितले.

समुद्रात बोट उलटून एकाचा मृत्यू

मुंबई : मुंबईतील खारदांडा मृत व्यक्तीचे नाव आहे. परिसरात बुधवारी सायंकाळी खार (पश्चिम) येथील वारीन मासेमारीसाठी गेलेली बोट समुद्रात पाडा लाईटहाऊसजवळ बुधवारी उलटून एका व्यक्तीचा मृत्यू झाला. सायंकाळी सव्वासहा वाजण्याच्या अशोक किशन राठोड (५५) असे सुमारास ही दुर्घटना घडली.

सहायक प्राध्यापक पदासाठी राज्यस्तरीय पात्रता परीक्षा (सेट) सावित्रीबाई फुले पुणे विद्यापीठ
(पूर्वीचे पुणे विद्यापीठ)
महाराष्ट्र शासन व गोवा शासन प्राधिकृत आणि यु.जी.सी., नवी दिल्ली मान्यताप्राप्त नोडल एजन्सी आयोजित
४१ व्या सेट परीक्षेची तारीख : रविवार, दि. २६ जुलै, २०२६
ऑनलाईन पद्धतीने अर्ज भरण्याची मुदत : ०२ जून, २०२६ ते १६ जून, २०२६
विलंब शुल्कासह अर्ज भरण्याची मुदत : १७ जून, २०२६ ते १९ जून, २०२६
सेट परीक्षेचा अर्ज ऑनलाईन पद्धतीने भरण्यासंबंधीची व या परीक्षेची संपूर्ण माहिती पुढील संकेतस्थळावर (https://setexam.unipune.ac.in) दि. ०२.०६.२०२६ पासून उपलब्ध होईल.
जाहिरात क्र. १२ प्रा. (डॉ.) प्रफुल्ल पवार
दि. २८/०५/२०२६ प्रभारी कुलसचिव तथा सदस्य सचिव (सेट)

केस, त्वचा व सर्व आरोग्य तक्रारींवर डॉ. मानसी तन्वी हर्बल क्लिनिक डॉ. पुष्कराज 9833683021 रोज फ्री चेकअप (ठाणे)
स्परिलिनी+ कॅप्सूलस, केशकलरा लेप, कुमकुमादी शतधौत घृत, मंत्रचिकित्सानुभव पुस्तक व तन्वी हर्बल प्रॉडक्ट्स उपलब्ध...

सिंधू संस्कृतीच्या अभ्यासक हरपल्या ज्येष्ठ पुरातत्त्वज्ञ शिरीन रत्नागर यांचे मुंबईत निधन
लोकसत्ता प्रतिनिधी
मुंबई : ज्येष्ठ पुरातत्त्वज्ञ शिरीन रत्नागर (८२) यांचे सोमवारी मुंबईत निधन झाले. सिंधू संस्कृतीविषयीच्या विशेषतः हडप्पाविषयीच्या, महत्त्वाच्या संशोधक-पुरातत्त्वज्ञ म्हणून त्या ओळखल्या जात होत्या. मागील काही वर्षांपासून त्या आजारी होत्या. प्राध्यापक म्हणून विद्यार्थ्यांना निवृत्तीनंतरही स्वतंत्र संशोधक म्हणून कार्यरत रत्नागर दीर्घ काळ दिल्ली येथील जवाहरलाल नेहरू विद्यापीठात प्राध्यापक म्हणून कार्यरत होत्या. त्याच दरम्यान रत्नागर यांनी प्रसिद्ध इतिहासतज्ज्ञ रोमिला थापर यांच्या मार्गदर्शनाखाली प्रबंध पूर्ण केला होता. निवृत्तीनंतरही त्या अनेक वर्षे स्वतंत्र संशोधक म्हणून कार्य करत होत्या. त्यांची 'एक्काउंटर्स: द वेस्टर्नली ट्रेड ऑफ द हडप्पन सिव्हिलायझेशन', 'हडप्पन आर्कियोलॉजी: अर्ली स्टेट परस्पेक्टिव्ह' आणि 'द एंड ऑफ द ग्रेट हडप्पन ट्रेडिशन' आदी पुस्तके प्रसिद्ध आहेत. घडविण्यातही त्यांनी योगदान दिले. शिरीन रत्नागर यांचा जन्म १९४४ साली मुंबईत झाला. त्यांचे शालेय शिक्षण मुंबईतील पारशी गर्ल्स हायस्कूलमध्ये झाले. त्यानंतर इतिहास विषयात पदवी अभ्यासक्रम पूर्ण केल्यानंतर त्यांनी पुण्यातील डेक्कन महाविद्यालयात एच. डी. सांकलिया यांच्या मार्गदर्शनाखाली पुरातत्त्वशास्त्राचे शिक्षण घेतले.

बायर क्रॉपसायन्स लिमिटेड
(नोंदणीकृत कार्यालय: बायर हाऊस, सेंट्रल अ‍ॅव्हेन्यू, हिरानंदानी ईस्टेट, ठाणे ४००६०७, सीआयएन: एल२४२९०एमएच९५८पीएलसी०९९१७३)
३१ मार्च, २०२६ रोजी संपलेल्या तिमाही आणि वार्षिक वित्तीय निष्कर्षांच्या विवरणाचा उतारा
₹ दशलक्ष

तपशील	संपलेली तिमाही			संपलेले वर्ष	
	३१.०३.२०२६	३१.१२.२०२५	३१.०३.२०२५	३१.०३.२०२६	३१.०३.२०२५
अलेखापरिहित				लेखापरिहित	लेखापरिहित
प्रवर्तनातून एकूण उत्पन्न	११,००८	११,०६२	१०,४६४	५६,७५०	५४,७३४
कालावधी/ वर्षासाठी करपूर्व निव्वळ नफा	२,०६४	१,९३०	१,६७९	८,५४९	७,०७४
कालावधी/ वर्षासाठी करोत्तर निव्वळ नफा	१,६२९	१,५७०	१,४३३	६,८९२	५,६८०
कालावधी/ वर्षासाठी एकूण सर्वसमावेशक उत्पन्न	१,५३९	१,२८८	१,३९९	६,७७९	५,६२८
समभाग भांडवल	४४९	४४९	४४९	४४९	४४९
राखीव (ताळेबंदानुसार पुनर्मुल्यांकित राखीव वगळून)	-	-	-	२९,२०८	२८,०५५
प्रति समाभाग प्राप्ती (प्रत्येकी ₹१०/- चे) मुलभूत आणि सौम्यकृत (अवार्षिक) (₹ मध्ये)	३६.०७ ^१	२९.२९ ^१	३९.८८ ^१	१५३.३५	१२६.३८

टीप: वरील माहिती म्हणजे सेबी (लिस्टिंग ऑब्लिगेशन्स अँड डिस्क्लोजर रिक्वायरमेंट्स) रेग्युलेशन्स, २०१५ च्या रेग्युलेशन ३३ अंतर्गत स्टॉक एक्सचेंजकडे सादर केलेल्या ३१ मार्च, २०२६ रोजी संपलेल्या तिमाही आणि वार्षिक वित्तीय निष्कर्षांच्या तपशिलवार विवरणाचा उतारा आहे. वित्तीय निष्कर्षांचे संपूर्ण विवरण स्टॉक एक्सचेंजची वेबसाईट www.bseindia.com वर आणि कंपनीची वेबसाईट www.bayer.in वर इन्व्हेस्टर रिलेशन विभागा अंतर्गत उपलब्ध आहे. ते क्युआर कोड स्कॅन करून पाहता येईल.

टिकाण: मुंबई दिनांक: २६ मे, २०२६

संचालक मंडळाच्या आदेशावरून विनित जिंदाल कार्यकारी संचालक आणि मुख्य वित्तीय अधिकारी डीआयएन: १०८४९४६५

SUPRIYA LIFESCIENCE LIMITED
CIN No: L51900MH2008PLC180452
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

EXTRACT OF AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2026
(₹ In million)

Sr. No.	Particulars	Quarter ended 31-03-2026	Quarter ended 31-12-2025	Quarter ended 31-03-2025	Year ended 31-03-2026	Year ended 31-03-2025
		Audited	Unaudited	Audited	Audited	Audited
1	Total revenue from operations	2,765.28	2,064.40	1,841.09	8,278.75	6,964.85
2	Net Profit/(Loss) for the period (before tax, Exceptional items)	921.29	673.78	640.62	2,752.37	2,484.81
3	Net Profit/(Loss) for the period before Tax (after Exceptional items)	921.29	669.20	640.62	2,747.79	2,484.81
4	Net Profit/(Loss) for the period after Tax (after Exceptional items)	742.29	496.75	503.82	2,091.20	1,879.58
5	Total Comprehensive income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax)	742.70	497.15	504.69	2,090.21	1,878.33
6	Equity Share capital	160.97	160.97	160.97	160.97	160.97
7	Other Equity				11,816.36	9,806.63
8	Earning per share (of ₹ 2/- each) (not annualised for the Quarters)					
	1. Basic	9.22	6.17	6.29	25.98	23.35
	2. Diluted	9.22	6.17	6.29	25.98	23.35

Notes:
a) The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on May 27, 2026.
b) The figures for quarters ended March 31, 2026 and March 31, 2025 are balancing figures between the audited figures in respect of the full financial year and published year to date unaudited figures upto the third quarter of the respective financial year, which were subjected to Limited Review by the Statutory Auditors.
c) The above is an extract of the detailed format of Quarterly and Year Ended Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The full format of the statement of financial results are available on the stock exchange websites: www.bseindia.com, www.nseindia.com and also on Company's website. The same can also be accessed by scanning the QR code provided below.

Place: Mumbai Date: May 27, 2026

For Supriya Lifescience Limited Sd/-
Dr. Satish Waman Wagh
Chairman and Executive Director
DIN: 01456982

Sustainability. Growth. Profitability.

ताकद जी उभी रहाते प्रत्येक जोखमीच्या मागे
आपकाले रक्षियाणि **GIC Re**

एकूण प्रीमियम	करोत्तर नफा		पतदारी		निव्वळ संपत्ती		
	31.03.2026	31.03.2025	31.03.2026	31.03.2025	31.03.2026	31.03.2025	
44,007	41,154	8,392	6,701	4.21	3.70	51,301	43,107

(₹ कोटींमध्ये) (₹ कोटींमध्ये) (₹ कोटींमध्ये) (₹ कोटींमध्ये) (₹ कोटींमध्ये) (₹ कोटींमध्ये)

31 मार्च 2026 रोजी संपलेली तिमाही आणि वर्षासाठीचे वित्तीय निष्कर्ष
₹ कोटींमध्ये

अनु. क्र.	तपशील	स्टॅंडअलोन			कॉन्सॉलिडेटेड		
		संपलेली तिमाही (तीन महिने)	वर्ष ते तारीख आकडेवारी (तीन महिने)	मागील वर्षातील संपलेले संबंधित तीन महिने	संपलेली तिमाही (तीन महिने)	वर्ष ते तारीख आकडेवारी (तीन महिने)	मागील वर्षातील संपलेले संबंधित तीन महिने
		(31/03/2026)	(31/03/2026)	(31/03/2025)	(31/03/2026)	(31/03/2026)	(31/03/2025)
1	परिचालनातील एकूण उत्पन्न \$	11,030	44,007	10,367	11,161	44,368	10,746
2	कालावधीसाठी निव्वळ नफा/(तोटा) (कर, अपवादालेख आणि /किंवा अनन्यसाधारण बाबींच्या आधी#)	2,960	10,793	2,923	3,108	11,447	3,144
3	कालावधीसाठी कर-पूर्व निव्वळ नफा/(तोटा) (अपवादालेख आणि /किंवा अनन्यसाधारण बाबींच्या नंतर#)	2,960	10,793	2,923	3,108	11,447	3,144
4	कालावधीसाठी कर-पश्चात निव्वळ नफा/(तोटा) (अपवादालेख आणि /किंवा अनन्यसाधारण बाबींच्या नंतर#)	2,254	8,392	2,183	2,533	9,662	2,499
5	कालावधीसाठी एकूण सर्वसमावेशक उत्पन्न (ज्यात कालावधीसाठी नफा / (तोटा) (करपश्चात) आणि इतर सर्वसमावेशक उत्पन्न (करपश्चात) ह्यांचा समावेश आहे)	2,254	8,392	2,183	2,533	9,662	2,499
6	सम भाग भांडवल	877	877	877	877	877	877
7	मागील वर्षाच्या लेखापरीक्षित ताळेबंदामध्ये दाखवलेला राखीवनिधी (पुनर्मुल्यांकन राखीवनिधी वगळता)	52,861	52,861	43,927	58,419	58,419	47,782
8	प्रति शेअर मिळकत (प्रत्येकी ₹ 5/-) (सुरू असलेल्या आणि खंडित केलेल्या परिचालनासाठी)	12.85	47.84	12.44	14.44	55.08	14.24
1	मूलभूत:	12.85	47.84	12.44	14.44	55.08	14.24
2	वित्तलत:	12.85	47.84	12.44	14.44	55.08	14.24

टीप: वरील उतारा हा सेबी (सूचीबद्धता द्यायचे आणि प्रकटीकरण आवश्यकता) विनियम, 2015 च्या रेग्युलेशन 33 च्या अंतर्गत स्टॉक एक्सचेंजकडे दाखल केलेल्या तिमाही आणि आज रोजीचे वर्ष ह्यांच्या वित्तीय निष्कर्षांच्या तपशीलवार स्वरूपाचा आहे. तिमाही आणि आज रोजीचे वर्ष ह्यांचे संपूर्ण स्वरूपातील वित्तीय निष्कर्ष लेखापरीक्षकाच्या अहवालासह, (www.bseindia.com) आणि (www.nseindia.com) ह्या स्टॉक एक्सचेंजेसच्या वेबसाइटवर उपलब्ध आहेत आणि (https://www.gicre.in/images/2026/Outcome_of_Board_Meeting_final_signed_26th_May_2026.pdf) ह्या कॉर्पोरेशनच्या वेबसाइटवर पोस्ट केले आहेत आणि क्युआर कोड स्कॅन करून ते बघता येतील.
ख. \$ परिचालनातून मिळणारे एकूण उत्पन्न म्हणजे एकूण लिखित प्रीमियम, पुनर्निव्वळणी एकूण रकम आणि निव्वळ लागू कर.

जानरल इन्शुरन्स कॉर्पोरेशन ऑफ इंडियासाठी आणि वतीने **द्वितेश जोशी**
ईडी (अॅडिशनल चार्ज ऑफ सीएमडी)
DIN: 09322218

भारतीय सर्वसाधारण विमा महामंडळ
'सुरक्षा', 170, जमशेदजी टाटा रोड, चर्चगेट, मुंबई 400020, भारत | टेलिफोन (बोर्ड): +91 022 2286 7000 • ईमेल: investors.gic@gicre.in
आयआरडीएआय नोंदणी क्रमांक: 112 सीआयएन: L67200MH1972GOI016133 www.gicre.in